Olutasidenib

85 interactions 21 cited references

Also sold as: Rezlidhia Rezlidhia®

About Olutasidenib

Olutasidenib is used to treat a certain type of acute myeloid leukemia (AML; a type of cancer that begins in the white blood cells) that has returned or that has not improved after previous treatment(s). Olutasidenib is in a class of medications called IDH1 inhibitors. It works by slowing or stopping the growth of canc… Read the full Olutasidenib drug information page →

Medically reviewed by Dr. Brian Staiger, PharmD, BCPS · Updated Aug 10, 2026 · Editorial policy · Data sources

Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →

Most serious with: Dengue Tetravalent Vaccine, Live Smallpox Monkeypox Vaccine Measles Virus Vaccine, Live Yellow Fever Vaccine Bacillus Of Calmette And Guerin Vaccine, Live Rubella Virus Vaccine, Live

9 Contraindicated 76 Major

All (85) Contraindicated (9) Major (76)

Contraindicated

Olutasidenib Bacillus Of Calmette And Guerin Vaccine, Live An increased risk of infection by the live vaccine Details Olutasidenib Dengue Tetravalent Vaccine, Live An increased risk of infection by the live vaccine Details Olutasidenib Measles Virus Vaccine, Live An increased risk of infection by the live vaccine Details Olutasidenib Mumps Virus Vaccine, Live An increased risk of infection by the live vaccine Details Olutasidenib Rubella Virus Vaccine, Live An increased risk of infection by the live vaccine Details Olutasidenib Smallpox Monkeypox Vaccine An increased risk of infection by the live vaccine Details Olutasidenib Typhoid Vaccine Typhim VI® An increased risk of infection by the live vaccine Details Olutasidenib Varicella Virus Vaccine, Live An increased risk of infection by the live vaccine Details Olutasidenib Yellow Fever Vaccine Stamaril An increased risk of infection by the live vaccine Details

Major

Olutasidenib Simvastatin Flolipid Reduced sensitive CYP3A substrate exposure Details Olutasidenib Acalabrutinib Calquence Reduced sensitive CYP3A substrate exposure Details Olutasidenib Avapritinib Ayvakit Reduced sensitive CYP3A substrate exposure Details Olutasidenib Avanafil Stendra Reduced sensitive CYP3A substrate exposure Details Olutasidenib Bosutinib Bosulif Reduced sensitive CYP3A substrate exposure Details Olutasidenib Budesonide Entocort Reduced sensitive CYP3A substrate exposure Details Olutasidenib Budesonide Nasal Spray Rhinocort Reduced sensitive CYP3A substrate exposure Details Olutasidenib Budesonide Oral Inhalation Pulmicort Reduced sensitive CYP3A substrate exposure Details Olutasidenib Cobimetinib Cotellic Reduced sensitive CYP3A substrate exposure Details Olutasidenib Dasatinib Phyrago Reduced sensitive CYP3A substrate exposure Details Olutasidenib Entrectinib Rozlytrek Reduced sensitive CYP3A substrate exposure Details Olutasidenib Everolimus Afinitor Reduced sensitive CYP3A substrate exposure Details Olutasidenib Felodipine Plendil® Reduced sensitive CYP3A substrate exposure Details Olutasidenib Finerenone Kerendia Reduced sensitive CYP3A substrate exposure Details Olutasidenib Ibrexafungerp Brexafemme Reduced sensitive CYP3A substrate exposure Details Olutasidenib Ibrutinib Imbruvica Reduced sensitive CYP3A substrate exposure Details Olutasidenib Ivabradine Corlanor Reduced sensitive CYP3A substrate exposure Details Olutasidenib Lovastatin Altocor® Reduced sensitive CYP3A substrate exposure Details Olutasidenib Lurasidone Latuda Reduced sensitive CYP3A substrate exposure Details Olutasidenib Maraviroc Selzentry Reduced sensitive CYP3A substrate exposure Details Olutasidenib Midazolam Nasal Spray Nayzilam Reduced sensitive CYP3A substrate exposure Details Olutasidenib Midazolam Injection Nayzilam Reduced sensitive CYP3A substrate exposure Details Olutasidenib Nafcillin Injection Unipen® Injection Reduced olutasidenib exposure Details Olutasidenib Naloxegol Movantik Reduced sensitive CYP3A substrate exposure Details Olutasidenib Adenovirus Vaccine Type 4, Live An increased risk of infection by the live vaccine Details Olutasidenib Adenovirus Vaccine Type 7, Live An increased risk of infection by the live vaccine Details Olutasidenib Alfentanil Reduced sensitive CYP3A substrate exposure Details Olutasidenib Apalutamide Erleada Reduced olutasidenib exposure Details Olutasidenib Aprepitant Aponvie Reduced sensitive CYP3A substrate exposure Details Olutasidenib Bosentan Reduced olutasidenib exposure Details Olutasidenib Buspirone Bucapsol Reduced sensitive CYP3A substrate exposure Details

Check another drug

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist

Educational information only, not medical advice. Always confirm interactions with your pharmacist or prescriber before making any change to your medications.